β-blockade with nebivolol for prevention of acute ischaemic events in elderly patients with heart failure
Aim. This subanalysis of the Study of the Effects of Nebivolol Intervention on Outcomes and Hospitalisation in Seniors with Heart Failure (SENIORS) investigates whether treatment with nebivolol, a β-blocker with nitric oxide-releasing properties, can provide additional benefits besides its effects o...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«SILICEA-POLIGRAF» LLC
2011-08-01
|
| Series: | Кардиоваскулярная терапия и профилактика |
| Online Access: | https://cardiovascular.elpub.ru/jour/article/view/1899 |
| _version_ | 1797882622761762816 |
|---|---|
| author | G. Ambrosio M. D. Flather M. Böhm A. J.S. Coats L. Tavazzi D. J. van Veldhuisen M. G. Conti G. Spinucci F. Mascagni A. Murrone A. Cohen-Solal |
| author_facet | G. Ambrosio M. D. Flather M. Böhm A. J.S. Coats L. Tavazzi D. J. van Veldhuisen M. G. Conti G. Spinucci F. Mascagni A. Murrone A. Cohen-Solal |
| author_sort | G. Ambrosio |
| collection | DOAJ |
| description | Aim. This subanalysis of the Study of the Effects of Nebivolol Intervention on Outcomes and Hospitalisation in Seniors with Heart Failure (SENIORS) investigates whether treatment with nebivolol, a β-blocker with nitric oxide-releasing properties, can provide additional benefits besides its effects on heart failure (HF), by reducing cardiac ischaemic events in patients with HF of ischaemic aetiology. Material and methods. A double-blind, randomised, placebo-controlled, multicentre trial of nebivolol in 2128 elderly patients. For this analysis, data were extracted for 2128 elderly (≥70 years) HF patients in whom coronary artery disease (CAD) was the underlying aetiology (68,2 %; 717 placebo-treated patients and 735 assigned to nebivolol). The main endpoint was the composite of cardiac ischaemic events at 2 year follow-up: death/hospitalisation for myocardial infarction, unstable angina or sudden death, as originally identified in the case report form. Results. At follow-up, nebivolol treatment was associated with a one-third reduction in the risk of ischaemic events, the composite endpoint occurring in 15,9 % of placebo and 10,7 % of nebivolol-treated patients (HR 0,68; 95 % CI 0,51 to 0,90; p=0,008). This effect was independent of age, gender and ejection fraction. No difference in this composite endpoint was observed in the subgroup of patients of non-ischaemic aetiology. Conclusion. Nebivolol was effective in reducing cardiac ischaemic events in patients with HF of ischaemic aetiology. The prevention of ischaemic events can be an additional beneficial effect of β-blockade in HF patients with underlying CAD. |
| first_indexed | 2024-04-10T03:38:47Z |
| format | Article |
| id | doaj.art-cb29e589614d41c7a979c2bd0332313e |
| institution | Directory Open Access Journal |
| issn | 1728-8800 2619-0125 |
| language | Russian |
| last_indexed | 2024-04-10T03:38:47Z |
| publishDate | 2011-08-01 |
| publisher | «SILICEA-POLIGRAF» LLC |
| record_format | Article |
| series | Кардиоваскулярная терапия и профилактика |
| spelling | doaj.art-cb29e589614d41c7a979c2bd0332313e2023-03-13T07:23:19Zrus«SILICEA-POLIGRAF» LLCКардиоваскулярная терапия и профилактика1728-88002619-01252011-08-01104697610.15829/1728-8800-2011-4-69-761614β-blockade with nebivolol for prevention of acute ischaemic events in elderly patients with heart failureG. Ambrosio0M. D. Flather1M. Böhm2A. J.S. Coats3L. Tavazzi4D. J. van Veldhuisen5M. G. Conti6G. Spinucci7F. Mascagni8A. Murrone9A. Cohen-Solal10Division of Cardiology, University of Perugia School of MedicineClinical Trials and Investigation Unit, Royal Brompton and Harefield NHS TrustKlinik für Innere Medizin III, Universität des SaarlandesFaculty of Medicine, University of SydneyDepartment of Cardiology, IRCCS Policlinico San MatteoDepartment of Cardiology, University Medical Center Groningen, University of GroningenDivision of Cardiology, University of Perugia School of MedicineDivision of Cardiology, University of Perugia School of MedicineData Management & Biometry Unit, CAST and TRIALDivision of Cardiology, University of Perugia School of MedicineINSERM U942; Faculté Paris 7 Paris Diderot; Hopital LariboisiereAim. This subanalysis of the Study of the Effects of Nebivolol Intervention on Outcomes and Hospitalisation in Seniors with Heart Failure (SENIORS) investigates whether treatment with nebivolol, a β-blocker with nitric oxide-releasing properties, can provide additional benefits besides its effects on heart failure (HF), by reducing cardiac ischaemic events in patients with HF of ischaemic aetiology. Material and methods. A double-blind, randomised, placebo-controlled, multicentre trial of nebivolol in 2128 elderly patients. For this analysis, data were extracted for 2128 elderly (≥70 years) HF patients in whom coronary artery disease (CAD) was the underlying aetiology (68,2 %; 717 placebo-treated patients and 735 assigned to nebivolol). The main endpoint was the composite of cardiac ischaemic events at 2 year follow-up: death/hospitalisation for myocardial infarction, unstable angina or sudden death, as originally identified in the case report form. Results. At follow-up, nebivolol treatment was associated with a one-third reduction in the risk of ischaemic events, the composite endpoint occurring in 15,9 % of placebo and 10,7 % of nebivolol-treated patients (HR 0,68; 95 % CI 0,51 to 0,90; p=0,008). This effect was independent of age, gender and ejection fraction. No difference in this composite endpoint was observed in the subgroup of patients of non-ischaemic aetiology. Conclusion. Nebivolol was effective in reducing cardiac ischaemic events in patients with HF of ischaemic aetiology. The prevention of ischaemic events can be an additional beneficial effect of β-blockade in HF patients with underlying CAD.https://cardiovascular.elpub.ru/jour/article/view/1899 |
| spellingShingle | G. Ambrosio M. D. Flather M. Böhm A. J.S. Coats L. Tavazzi D. J. van Veldhuisen M. G. Conti G. Spinucci F. Mascagni A. Murrone A. Cohen-Solal β-blockade with nebivolol for prevention of acute ischaemic events in elderly patients with heart failure Кардиоваскулярная терапия и профилактика |
| title | β-blockade with nebivolol for prevention of acute ischaemic events in elderly patients with heart failure |
| title_full | β-blockade with nebivolol for prevention of acute ischaemic events in elderly patients with heart failure |
| title_fullStr | β-blockade with nebivolol for prevention of acute ischaemic events in elderly patients with heart failure |
| title_full_unstemmed | β-blockade with nebivolol for prevention of acute ischaemic events in elderly patients with heart failure |
| title_short | β-blockade with nebivolol for prevention of acute ischaemic events in elderly patients with heart failure |
| title_sort | β blockade with nebivolol for prevention of acute ischaemic events in elderly patients with heart failure |
| url | https://cardiovascular.elpub.ru/jour/article/view/1899 |
| work_keys_str_mv | AT gambrosio bblockadewithnebivololforpreventionofacuteischaemiceventsinelderlypatientswithheartfailure AT mdflather bblockadewithnebivololforpreventionofacuteischaemiceventsinelderlypatientswithheartfailure AT mbohm bblockadewithnebivololforpreventionofacuteischaemiceventsinelderlypatientswithheartfailure AT ajscoats bblockadewithnebivololforpreventionofacuteischaemiceventsinelderlypatientswithheartfailure AT ltavazzi bblockadewithnebivololforpreventionofacuteischaemiceventsinelderlypatientswithheartfailure AT djvanveldhuisen bblockadewithnebivololforpreventionofacuteischaemiceventsinelderlypatientswithheartfailure AT mgconti bblockadewithnebivololforpreventionofacuteischaemiceventsinelderlypatientswithheartfailure AT gspinucci bblockadewithnebivololforpreventionofacuteischaemiceventsinelderlypatientswithheartfailure AT fmascagni bblockadewithnebivololforpreventionofacuteischaemiceventsinelderlypatientswithheartfailure AT amurrone bblockadewithnebivololforpreventionofacuteischaemiceventsinelderlypatientswithheartfailure AT acohensolal bblockadewithnebivololforpreventionofacuteischaemiceventsinelderlypatientswithheartfailure |